Culture Kalshi August 10, 2026
Hims builds out testosterone push ahead of next earnings call
What will Hims say during their next earnings call?
Kalshi prices this Testosterone at 97%. The reporting broadly agrees.
Hims & Hers Health is leaning into testosterone as a new product line, according to Stocktwits, which reports the telehealth company is mounting a fresh push around the hormone even as the GLP-1 weight-loss space becomes increasingly crowded. The specific question at issue is whether any company representative — including the call operator — says the word "testosterone" during the next Hims & Hers earnings call, including the Q&A portion. The market resolves on December 31, 2026. Traders put the probability at 97%, an overwhelming favorite, aligning with Stocktwits' reporting that the testosterone push is already underway.
Background
Hims & Hers Health, Inc. went public in 2021 via a SPAC merger and has built its business on direct-to-consumer telehealth treatments for hair loss, erectile dysfunction, skincare, and, more recently, weight loss. The company has been racing to capitalize on surging demand for GLP-1 medications like semaglutide, but that space has drawn heavy competition from both legacy players and newer telehealth entrants. Diversifying into testosterone replacement therapy represents a bid to open a new revenue lane. The earnings call will be the first chance for investors to hear management frame the testosterone product's role in the company's broader growth strategy.
The precedent
- Hims & Hers went public in January 2021 through a SPAC merger with Oaktree Acquisition Corp.
- Hims & Hers launched its GLP-1 weight loss program in late 2024, entering a market dominated by Novo Nordisk and Eli Lilly.
Context compiled by Crowdtells from the public record — verify before relying on it.
How outlets frame it
- Stocktwits: Frames Hims' testosterone push as part of a strategic pivot amid a crowded GLP-1 market, implying the company is seeking diversification beyond weight-loss medications.
What to watch
The next Hims & Hers earnings call — the event that determines whether "testosterone" is spoken on the record — has not yet been formally scheduled but must occur before the December 31, 2026 resolution date. Watch for the call announcement and whether prepared remarks or analyst questions prompt management to discuss the testosterone line by name.
The numbers behind this
Kalshi prices this Testosterone at 97%.
24h +1.0 pts
$51.7K traded · $15.8K in the last day · $34K open interest
Resolves on: If Testosterone is said by any Hims & Hers Health, Inc. representative (including the operator of the call) during the next Hims & Hers Health, Inc. earnings call (including the Q+A), then the market resolves to Yes.
Pricing Kalshi 97%
Sources
Frequently asked questions
What will Hims say during their next earnings call?
Kalshi prices this Testosterone at 97%. The reporting broadly agrees.
When does this market resolve?
This market resolves on: If Testosterone is said by any Hims & Hers Health, Inc. representative (including the operator of the call) during the next Hims & Hers Health, Inc. earnings call (including the Q+A), then the market resolves to Yes.
How are these odds set?
Prediction-market odds are prices set by people trading real money on the outcome, so the price reads as the crowd’s implied probability — not a guarantee or financial advice.
AI-written briefing grounded in 1 source and the live market, edited by Samuel Jo. Odds are crowd probabilities, not advice — how this works.